Showing results (131-140 of 3,591) with videos related to
Sort By:
Pageof 360
Journal of Viral Hepatitis|May 5, 2020
Prevalence and clinical features of patients with concurrent HBsAg and anti-HBs: Evaluation of the hepatitis B research network cohortWilliam M Lee, Wendy C King, Kathleen B Schwarz, et al.Journal of Viral Hepatitis|April 30, 2020
Response to direct-acting antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patientsItzíar Carrasco, Talía Sainz, Marie Antoinette Frick, et al.Journal of Viral Hepatitis|May 9, 2020
Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovirTae Seop Lim, Hyun Woong Lee, Jung Il Lee, et al.Journal of Viral Hepatitis|April 28, 2020
Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: A nationwide cohort studyChai Yeong Hong, Dong Hyun Sinn, Danbee Kang, et al.Journal of Viral Hepatitis|May 18, 2021
Hepatitis B virus genome diversity in adolescents: Tenofovir disoproxil fumarate treatment effect and HBeAg serocon versionChristophe Combet, Neeru Bhardwaj, Charlotte Hedskog, et al.Journal of Viral Hepatitis|May 18, 2021
Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortalityScott A McDonald, Stephen T Barclay, Hamish A Innes, et al.Journal of Viral Hepatitis|August 7, 2021
Cure everyone and vaccinate the rest: The patient perspective on future hepatitis B treatmentCatherine Freeland, Rhea Racho, Maureen Kamischke, et al.Journal of Viral Hepatitis|August 20, 2021
A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaignAnna Y Palmer, Kico Chan, Judy Gold, et al.Journal of Viral Hepatitis|August 20, 2021
The role of gut microbiota in hepatitis B disease progression and treatmentBryan Chen, Harry Huang, Calvin Q PanJournal of Viral Hepatitis|August 26, 2021
Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance - suggesting a valuable endpoint for early development HBV trialsFilip De Ridder, Milan J Sonneveld, Oliver Lenz, et al.Pageof 360